

Jerrold H Levy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8984181/publications.pdf>

Version: 2024-02-01

280
papers

22,580
citations

11908

72
h-index

10679

143
g-index

282
all docs

282
docs citations

282
times ranked

23920
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet Activation and Thrombosis in COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 055-061.	1.5	17
2	Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic. <i>Thrombosis and Haemostasis</i> , 2022, 122, 008-019.	1.8	11
3	Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Critical Care Medicine</i> , 2022, 50, e80-e86.	0.4	30
4	The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 1-9.	2.3	31
5	Consensus Statement: Hemostasis Trial Outcomes in Cardiac Surgery and Mechanical Support. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1026-1035.	0.7	9
6	Inhaled Pulmonary Vasodilator Therapy in Adult Lung Transplant. <i>JAMA Surgery</i> , 2022, 157, e215856.	2.2	10
7	Interpreting recent clinical studies for COVID-19: A continual process with more new data. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, 41, 101016.	0.6	3
8	Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. <i>Minerva Medica</i> , 2022, 112, .	0.3	7
9	Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines. <i>Journal of Intensive Care</i> , 2022, 10, 4.	1.3	0
10	Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management. <i>EClinicalMedicine</i> , 2022, 44, 101276.	3.2	21
11	Thrombin Generation in Cardiac Versus Noncardiac Surgical Cohorts. <i>Anesthesia and Analgesia</i> , 2022, 134, 606-614.	1.1	1
12	The Predictive Value of the 4Ts and HEP Score at Recommended Cutoffs in Patients With Mechanical Circulatory Support Devices. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, , .	0.6	4
13	Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 249-256.	2.3	28
14	Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study. <i>Anesthesiology</i> , 2022, 137, 67-78.	1.3	8
15	ECMO Outcomes, Transfusions, and Hemostatic Management: Quo Vadis?. <i>Annals of Thoracic Surgery</i> , 2022, , .	0.7	0
16	Management of urgent invasive procedures in patients treated with direct oral anticoagulants: An observational registry analysis. <i>Thrombosis Research</i> , 2022, 216, 106-112.	0.8	2
17	The risk of thromboembolic events with early intravenous 2– and 4–g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, double–blind, placebo–controlled, single–center trial. <i>Transfusion</i> , 2022, 62, .	0.8	3
18	How to manage anticoagulation during extracorporeal membrane oxygenation. <i>Intensive Care Medicine</i> , 2022, 48, 1076-1079.	3.9	24

#	ARTICLE	IF	CITATIONS
19	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	1.9	100
20	Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery. <i>Annals of Surgery</i> , 2021, 274, e204-e211.	2.1	27
21	Andexanet Alfa Use in Cardiac Surgical Patients: A Xa Inhibitor and Heparin Reversal Agent. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 265-266.	0.6	12
22	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 297-303.	1.9	27
23	Editorial commentary: Vascular injury in acute infections and COVID-19: everything old is new again. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 6-7.	2.3	9
24	COVID-19-associated Coagulopathy. <i>Anesthesiology</i> , 2021, 134, 366-369.	1.3	14
25	Recent advances in the research and management of sepsis-associated DIC. <i>International Journal of Hematology</i> , 2021, 113, 24-33.	0.7	46
26	Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. <i>International Journal of Hematology</i> , 2021, 113, 330-336.	0.7	16
27	Fibrin-modulating nanogels for treatment of disseminated intravascular coagulation. <i>Blood Advances</i> , 2021, 5, 613-627.	2.5	11
28	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1003-1011.	1.0	12
29	Commentary: Patient blood management in the era of coronavirus disease 2019—is anything really different?. <i>JTCVS Open</i> , 2021, 5, 97-98.	0.2	0
30	Key Pathogenic Factors in Coronavirus Disease 2019-associated Coagulopathy and Acute Lung Injury Highlighted in a Patient With Copresentation of Acute Myelocytic Leukemia: A Case Report. <i>A&A Practice</i> , 2021, 15, e01432.	0.2	1
31	Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 1740.	1.0	43
32	Cerebrospinal Fluid Proteome Changes in Older Non-Cardiac Surgical Patients with Postoperative Cognitive Dysfunction. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1281-1297.	1.2	9
33	Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference. <i>Journal of Trauma and Acute Care Surgery</i> , 2021, 91, S19-S25.	1.1	19
34	Viscoelastic testing to assess the effects of rapid fibrinogen concentrate administration after cardiopulmonary bypass: insights from the REPLACE study. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 359-365.	0.5	0
35	Endothelial Injury in COVID-19 and Acute Infections. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1774-1776.	1.1	17
36	Heated Humidified Breathing Circuit Rewarming in Hypothermic Patients Post-Cardiopulmonary Bypass—Pilot Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, , .	0.6	0

#	ARTICLE	IF	CITATIONS
37	Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia. <i>Chest</i> , 2021, 159, 2417-2427.	0.4	54
38	Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment. <i>Archives of Medical Research</i> , 2021, 52, 788-797.	1.5	32
39	COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 29-35.	0.7	37
40	Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm?. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 544-549.	0.5	11
41	A new SOFA score calculation to improve the predictive performance for mortality in sepsis-associated disseminated intravascular coagulopathy patients. <i>Journal of Critical Care</i> , 2021, 64, 108-113.	1.0	2
42	Heparin Resistance – Clinical Perspectives and Management Strategies. <i>New England Journal of Medicine</i> , 2021, 385, 826-832.	13.9	83
43	Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021). <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100919.	0.6	12
44	Comparison of Fibrin Monomers and D-dimers to predict thrombotic events in critically ill patients with COVID-19 pneumonia: A retrospective study. <i>Thrombosis Research</i> , 2021, 205, 8-10.	0.8	6
45	Pitfalls in Diagnosing Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, .	0.4	0
46	Proposal of the Definition for COVID-19-Associated Coagulopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 191.	1.0	83
47	Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 176.	1.8	10
48	Coagulopathy and Bleeding Management for Aortic Dissection Surgery. , 2021, , 577-593.		0
49	Can We Use Viscoelastic Testing to Evaluate Microvascular Dysfunction in Acute Myocardial Infarction?. <i>JACC Basic To Translational Science</i> , 2021, 6, 762-764.	1.9	0
50	Management of Chronically Anticoagulated Patients. , 2021, , 663-676.		0
51	Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 643-649.	1.3	60
52	Using Plasma and Prothrombin Complex Concentrates. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 032-037.	1.5	9
53	Enhanced Recovery After Cardiac Surgery (ERAS Cardiac) Recommendations: An Important First Step – But There Is Much Work to Be Done. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, 39-47.	0.6	61
54	Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 089-095.	1.5	124

#	ARTICLE	IF	CITATIONS
55	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 2302-2309.e6.	0.4	40
56	Pathophysiological Response to Trauma-Induced Coagulopathy: A Comprehensive Review. <i>Anesthesia and Analgesia</i> , 2020, 130, 654-664.	1.1	49
57	Controlled Multifactorial Coagulopathy: Effects of Dilution, Hypothermia, and Acidosis on Thrombin Generation In Vitro. <i>Anesthesia and Analgesia</i> , 2020, 130, 1063-1076.	1.1	20
58	The authors reply. <i>Critical Care Medicine</i> , 2020, 48, e989-e990.	0.4	0
59	Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3174-3183.	1.9	22
60	ISTH DIC subcommittee communication on anticoagulation in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2138-2144.	1.9	69
61	The authors reply. <i>Critical Care Medicine</i> , 2020, 48, e1160-e1161.	0.4	7
62	The Immunologic Effect of Early Intravenous Two and Four Gram Bolus Dosing of Tranexamic Acid Compared to Placebo in Patients With Severe Traumatic Bleeding (TAMPITI): A Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial. <i>Frontiers in Immunology</i> , 2020, 11, 2085.	2.2	26
63	Cryoprecipitate transfusion in bleeding patients. <i>Canadian Journal of Emergency Medicine</i> , 2020, 22, S4-S11.	0.5	3
64	Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2400-2407.	1.9	16
65	The coagulopathy, endotheliopathy, and vasculitis of COVID-19. <i>Inflammation Research</i> , 2020, 69, 1181-1189.	1.6	302
66	Coagulopathy of Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020, 48, 1358-1364.	0.4	412
67	Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations. <i>EClinicalMedicine</i> , 2020, 29-30, 100647.	3.2	17
68	Coagulation abnormalities and thrombosis in patients with COVID-19. <i>Lancet Haematology</i> , 2020, 7, e438-e440.	2.2	1,186
69	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1859-1865.	1.9	547
70	COVID-19 and its implications for thrombosis and anticoagulation. <i>Blood</i> , 2020, 135, 2033-2040.	0.6	1,892
71	The Contact Activation System: Problems and Paradoxes for Cardiac Anesthesiologists. <i>Anesthesia and Analgesia</i> , 2020, 131, 152-154.	1.1	0
72	In Response. <i>Anesthesia and Analgesia</i> , 2020, 130, e154-e156.	1.1	0

#	ARTICLE	IF	CITATIONS
73	RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers: Response to the Letter to the Editor by Dr Wada. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1507-1509.	1.9	1
74	Coagulopathy in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2103-2109.	1.9	453
75	The unique characteristics of COVID-19 coagulopathy. <i>Critical Care</i> , 2020, 24, 360.	2.5	366
76	Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 562-568.	1.0	19
77	Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. <i>Critical Care</i> , 2020, 24, 364.	2.5	118
78	More on Venous Thrombosis during Spaceflight. <i>New England Journal of Medicine</i> , 2020, 382, 1381-1382.	13.9	4
79	Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 740-747.	1.9	56
80	The influence of hyperglycemia on neutrophil extracellular trap formation and endothelial glycocalyx damage in a mouse model of type 2 diabetes. <i>Microcirculation</i> , 2020, 27, e12617.	1.0	26
81	The Developing Balance of Thrombosis and Hemorrhage in Pediatric Surgery: Clinical Implications of Age-Related Changes in Hemostasis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962092909.	0.7	26
82	Restarting Therapeutic Anticoagulation After Elective Craniotomy for Patients with Chronic Atrial Fibrillation: A Review of the Literature. <i>World Neurosurgery</i> , 2020, 137, 130-136.	0.7	5
83	Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. <i>Critical Care</i> , 2020, 24, 19.	2.5	124
84	Perioperative Thrombosis and Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 006-007.	1.5	4
85	Thromboinflammation and the hypercoagulability of COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1559-1561.	1.9	529
86	Sepsis-induced Coagulopathy and Disseminated Intravascular Coagulation. <i>Anesthesiology</i> , 2020, 132, 1238-1245.	1.3	99
87	Patient Blood Management. <i>Anesthesiology</i> , 2020, 133, 212-222.	1.3	62
88	Hypercoagulability and coronavirus disease 2019-associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms. <i>Journal of Trauma and Acute Care Surgery</i> , 2020, 89, e177-e181.	1.1	7
89	Arterial and venous thrombosis complicating coronary artery bypass grafting after use of epoetin alfa-epbx. <i>JTCVS Techniques</i> , 2020, 4, 154-155.	0.2	3
90	Protamine, is something fishy about it? The spectre of anaphylaxis continues. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2019, 33, 487-488.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential. <i>Critical Care</i> , 2019, 23, 280.	2.5	79
92	Ischemic limb necrosis in septic shock: What is the role of high-dose vasopressor therapy?. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1973-1978.	1.9	17
93	Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1989-1994.	1.9	325
94	Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis. <i>Critical Care</i> , 2019, 23, 302.	2.5	22
95	Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery: post hoc analysis and interpretation of phase III results. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 28, 566-574.	0.5	13
96	Protamine reversal of heparin: a fishy practice?. <i>Europace</i> , 2019, 21, 840-841.	0.7	1
97	Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. <i>Journal of Clinical Medicine</i> , 2019, 8, 728.	1.0	128
98	Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1265-1268.	1.9	37
99	Guidelines for Perioperative Care in Cardiac Surgery. <i>JAMA Surgery</i> , 2019, 154, 755.	2.2	593
100	The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. <i>Thrombosis Research</i> , 2019, 179, 11-14.	0.8	41
101	Effects of blood storage age on immune, coagulation, and nitric oxide parameters in transfused patients undergoing cardiac surgery. <i>Transfusion</i> , 2019, 59, 1209-1222.	0.8	2
102	Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961882404.	0.7	24
103	Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. <i>Vox Sanguinis</i> , 2019, 114, 374-385.	0.7	16
104	Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis?. <i>A&A Practice</i> , 2019, 13, 477-477.	0.2	9
105	Predicting mortality in patients with disseminated intravascular coagulation after cardiopulmonary bypass surgery by utilizing two scoring systems. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 11-16.	0.5	6
106	Maintaining Hemostatic Balance in Treating Disseminated Intravascular Coagulation. <i>Anesthesiology</i> , 2019, 131, 459-461.	1.3	1
107	Tranexamic Acid for Acute Hemorrhage. <i>Anesthesia and Analgesia</i> , 2019, 129, 1459-1461.	1.1	4
108	Derangement of the endothelial glycocalyx in sepsis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 283-294.	1.9	196

#	ARTICLE	IF	CITATIONS
109	How to interpret recent restrictive transfusion trials in cardiac surgery: More new data or new more data?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 1038-1040.	0.4	7
110	Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 415-419.	1.9	50
111	<i>Blood and Coagulation.</i> , 2019, , 837-848.		0
112	Protocolized hemostatic factor use in major thoracic aortic surgery. <i>Journal of Cardiovascular Surgery</i> , 2019, 60, 633-636.	0.3	4
113	Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery. <i>Anesthesiology</i> , 2018, 128, 390-400.	1.3	57
114	Reversal agents for non-vitamin K antagonist oral anticoagulants. <i>Nature Reviews Cardiology</i> , 2018, 15, 273-281.	6.1	116
115	Supplementary fibrinogen in the management of bleeding: re-evaluation of data from clinical trials. <i>British Journal of Anaesthesia</i> , 2018, 120, 407-409.	1.5	3
116	Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1020-1026.	0.7	32
117	Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 231-241.	1.9	333
118	Antifibrinolytic Therapy and Perioperative Considerations. <i>Anesthesiology</i> , 2018, 128, 657-670.	1.3	103
119	Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 170-174.	1.9	34
120	Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 54-64.	1.9	41
121	Journal-related Activities and Other Special Activities at the 2018 American Society of Anesthesiologists Meeting. <i>Anesthesiology</i> , 2018, 129, 634-643.	1.3	0
122	The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review. <i>International Journal of Emergency Medicine</i> , 2018, 11, 55.	0.6	25
123	Bacterial contamination of platelets for transfusion: strategies for prevention. <i>Critical Care</i> , 2018, 22, 271.	2.5	97
124	Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis. <i>Thrombosis Research</i> , 2018, 171, 1-6.	0.8	39
125	Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 145S-149S.	0.7	11
126	Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal. <i>Anesthesiology</i> , 2018, 129, 1171-1184.	1.3	27

#	ARTICLE	IF	CITATIONS
127	Perioperative coagulation management: Evolving strategies. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2018, 37, 317-318.	0.6	0
128	Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers. <i>British Journal of Anaesthesia</i> , 2018, 121, 758-767.	1.5	45
129	Use of factor concentrates for the management of perioperative bleeding: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2113-2115.	1.9	0
130	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE ADâ„¢ study. <i>Journal of Medical Economics</i> , 2017, 20, 435-442.	1.0	7
131	The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1317-1321.	1.9	46
132	Adjuncts to Blood Component Therapies for the Treatment of Bleeding in the Intensive Care Unit. <i>Transfusion Medicine Reviews</i> , 2017, 31, 258-263.	0.9	5
133	Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques. <i>Vox Sanguinis</i> , 2017, 112, 443-452.	0.7	94
134	Technology: Is There Sufficient Evidence to Change Practice in Point-of-Care Management of Coagulopathy?. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, 1849-1856.	0.6	11
135	Therapeutic Plasma Transfusion in Bleeding Patients: A Systematic Review. <i>Anesthesia and Analgesia</i> , 2017, 124, 1268-1276.	1.1	25
136	Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. <i>New England Journal of Medicine</i> , 2017, 376, 2032-2042.	13.9	225
137	New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. <i>BMJ Open</i> , 2017, 7, e017046.	0.8	230
138	What is the evidence for platelet transfusion in perioperative settings?. <i>Vox Sanguinis</i> , 2017, 112, 704-712.	0.7	19
139	Precision Correction of Coagulopathy or Prothrombin Complex Concentrates?. <i>Anesthesiology</i> , 2017, 127, 744-746.	1.3	6
140	Idarucizumab for Dabigatran Reversal â€” Full Cohort Analysis. <i>New England Journal of Medicine</i> , 2017, 377, 431-441.	13.9	858
141	Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting. <i>Anesthesia and Analgesia</i> , 2016, 122, 1287-1300.	1.1	84
142	Perioperative management of the bleeding patient. <i>British Journal of Anaesthesia</i> , 2016, 117, iii18-iii30.	1.5	113
143	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016, 20, 115.	2.5	40
144	Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. <i>American Journal of Medicine</i> , 2016, 129, S47-S53.	0.6	17

#	ARTICLE	IF	CITATIONS
145	Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. <i>Critical Care</i> , 2016, 20, 273.	2.5	19
146	Does moderate hypothermia really carry less bleeding risk than deep hypothermia for circulatory arrest? A propensity-matched comparison in hemiarth replacement. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 1559-1569.e2.	0.4	41
147	Discontinuation and management of direct-acting anticoagulants for emergency procedures. <i>American Journal of Emergency Medicine</i> , 2016, 34, 14-18.	0.7	31
148	When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 623-627.	1.9	285
149	Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial. <i>Canadian Journal of Anaesthesia</i> , 2016, 63, 1223-1232.	0.7	18
150	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. <i>American Heart Journal</i> , 2016, 182, 62-71.	1.2	23
151	Antithrombin: anti-inflammatory properties and clinical applications. <i>Thrombosis and Haemostasis</i> , 2016, 115, 712-728.	1.8	138
152	Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. <i>British Journal of Anaesthesia</i> , 2016, 117, 41-51.	1.5	110
153	3-Factor Prothrombin Complex Concentrates in Infants With Refractory Bleeding After Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2016, 30, 1627-1631.	0.6	18
154	Idarucizumab for dabigatran overdose. <i>Clinical Toxicology</i> , 2016, 54, 644-646.	0.8	30
155	Letter to the Editor. <i>Journal of Intensive Care Medicine</i> , 2016, 31, 70-71.	1.3	0
156	Edoxaban in the secondary prevention of VTE. <i>Lancet Haematology</i> , 2016, 3, e208-e209.	2.2	0
157	The Judicious Use of Recombinant Factor VIIa. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 125-132.	1.5	28
158	Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. <i>Expert Review of Hematology</i> , 2016, 9, 115-122.	1.0	51
159	Three Factor Prothrombin Complex Concentrates in Cardiac Surgery: A Novel Algorithmic Approach to Perioperative Bleeding. <i>Blood</i> , 2016, 128, 5035-5035.	0.6	2
160	Management of Chronically Anticoagulated Patients. , 2016, , 529-542.		0
161	How I use fibrinogen replacement therapy in acquired bleeding. <i>Blood</i> , 2015, 125, 1387-1393.	0.6	137
162	Prothrombin Complex Concentrates in Trauma and Perioperative Bleeding. <i>Anesthesiology</i> , 2015, 122, 923-931.	1.3	88

#	ARTICLE	IF	CITATIONS
163	Antifibrinolytic Therapy for Cardiac Surgery. <i>Anesthesiology</i> , 2015, 123, 214-221.	1.3	89
164	Factor Concentrates for Perioperative Bleeding. <i>Anesthesia and Analgesia</i> , 2015, 121, 4-5.	1.1	0
165	Editorial Comment. <i>A & A Case Reports</i> , 2015, 4, 125-126.	0.7	0
166	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thrombosis and Haemostasis</i> , 2015, 114, 198-205.	1.8	132
167	Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015, 169, 751-757.	1.2	69
168	Point of Care and Factor Concentrate-Based Coagulation Algorithms. <i>Transfusion Medicine and Hemotherapy</i> , 2015, 42, 115-121.	0.7	36
169	Anticoagulation management associated with extracorporeal circulation. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2015, 29, 189-202.	1.7	31
170	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , 2015, 373, 511-520.	13.9	1,419
171	Protocol Adherence When Managing Massive Bleeding Following Complex Cardiac Surgery: A Study Design Pilot. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015, 29, 303-310.	0.6	11
172	Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. <i>Critical Care</i> , 2015, 19, 203.	2.5	77
173	Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons. <i>Neurochemical Research</i> , 2015, 40, 2220-2229.	1.6	19
174	Prothrombin Complex Concentrates and Cardiac Surgery. <i>Blood</i> , 2015, 126, 4712-4712.	0.6	1
175	Direct Oral Anticoagulants. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1333-1351.	1.1	81
176	In reply. <i>Transfusion</i> , 2014, 54, 1443-1444.	0.8	0
177	Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1428-1436.	1.9	181
178	Impact of Perioperative Blood Pressure Variability on Health Resource Utilization After Cardiac Surgery: An Analysis of the ECLIPSE Trials. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014, 28, 579-585.	0.6	12
179	Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. <i>Transfusion</i> , 2014, 54, 1389-1405.	0.8	259
180	Dabigatran-related coagulopathy: when can we assume the effect has "worn off"? <i>American Journal of Emergency Medicine</i> , 2014, 32, 1433-1434.	0.7	1

#	ARTICLE	IF	CITATIONS
181	Novel oral anticoagulation agents: New drugs create new paradigms. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 1802-1803.	0.4	1
182	The Influence of Various Patient Characteristics on D-dimer Concentration in Critically Ill Patients and Its Role as a Prognostic Indicator in the Intensive Care Unit Setting. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 675-686.	0.7	25
183	Anticoagulants. <i>Clinics in Laboratory Medicine</i> , 2014, 34, xiii-xv.	0.7	0
184	New Oral Anticoagulantâ€“Induced Bleeding. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 575-586.	0.7	17
185	Clinical Use of the Activated Partial Thromboplastin Time and Prothrombin Time for Screening. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 453-477.	0.7	96
186	Anticoagulation Strategies for the Management of Postoperative Atrial Fibrillation. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 537-561.	0.7	31
187	Off-Label Use of Recombinant Human Factor VIIa. <i>Annals of Thoracic Surgery</i> , 2014, 98, 393-395.	0.7	6
188	Pharmacology and Safety of New Oral Anticoagulants. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 443-452.	0.7	8
189	Perioperative Management of Patients Receiving New Oral Anticoagulants. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 637-654.	0.7	24
190	Cryoprecipitate therapy. <i>British Journal of Anaesthesia</i> , 2014, 113, 922-934.	1.5	161
191	Safe Application of a Restrictive Transfusion Protocol in Moderate-Risk Patients Undergoing Cardiac Operations. <i>Annals of Thoracic Surgery</i> , 2014, 97, 1630-1635.	0.7	21
192	Editorial Comment. <i>A & A Case Reports</i> , 2014, 2, 95.	0.7	1
193	Role of Coagulation Factor Concentrates for Reversing Dabigatran-related Anticoagulation. <i>Anesthesiology</i> , 2014, 120, 1316-1318.	1.3	4
194	In Reply. <i>Anesthesiology</i> , 2014, 120, 243-243.	1.3	0
195	Post Hoc Analysis of Desirudin Versus Enoxaparin for Thromboprophylaxis in High-Risk Patients Undergoing Elective Hip Replacement Surgery. <i>Blood</i> , 2014, 124, 5086-5086.	0.6	0
196	Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo-controlled, multicenter clinical trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 927-939.	0.4	75
197	Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. <i>Transfusion</i> , 2013, 53, 1120-1131.	0.8	70
198	Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 1077-1082.e4.	0.4	18

#	ARTICLE	IF	CITATIONS
199	Point of Care Devices for Assessing Bleeding and Coagulation in the Trauma Patient. <i>Anesthesiology Clinics</i> , 2013, 31, 55-65.	0.6	35
200	Concepts of blood transfusion in adults. <i>Lancet, The</i> , 2013, 381, 1845-1854.	6.3	213
201	Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting. <i>Anesthesiology</i> , 2013, 118, 1466-1474.	1.3	158
202	Sepsis-Induced Disseminated Intravascular Coagulation, Symmetrical Peripheral Gangrene, and Amputations. <i>Critical Care Medicine</i> , 2013, 41, e290-e291.	0.4	18
203	A Case Series of Recombinant Platelet Factor 4 for Heparin Reversal After Cardiopulmonary Bypass. <i>Anesthesia and Analgesia</i> , 2012, 115, 1273-1278.	1.1	16
204	Fibrinogen and Hemostasis. <i>Anesthesia and Analgesia</i> , 2012, 114, 261-274.	1.1	265
205	Recombinant Activated Factor VII. <i>Anesthesia and Analgesia</i> , 2011, 113, 711-712.	1.1	19
206	Bleeding and management of coagulopathy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, 662-667.	0.4	84
207	Etiology and Assessment of Hypercoagulability with Lessons from Heparin-Induced Thrombocytopenia. <i>Anesthesia and Analgesia</i> , 2011, 112, 46-58.	1.1	14
208	VTE Prophylaxis with Desirudin in Patients with Thrombocytopenia: Insights From the DESIRABLE Trial. <i>Blood</i> , 2011, 118, 3293-3293.	0.6	0
209	Anesthetic concerns for patients with coagulopathy. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 400-405.	0.9	5
210	Multidisciplinary Approach to the Challenge of Hemostasis. <i>Anesthesia and Analgesia</i> , 2010, 110, 354-364.	1.1	142
211	Hereditary Angioedema. <i>Anesthesia and Analgesia</i> , 2010, 110, 1271-1280.	1.1	39
212	Heparin-induced thrombocytopenia and cardiac surgery. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 74-79.	0.9	36
213	Anticoagulation management during cardiopulmonary bypass: A survey of 54 North American institutions. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2010, 139, 1665-1666.	0.4	51
214	Safety of Recombinant Activated Factor VII in Randomized Clinical Trials. <i>New England Journal of Medicine</i> , 2010, 363, 1791-1800.	13.9	655
215	Antifibrinolytic therapy: new data and new concepts. <i>Lancet, The</i> , 2010, 376, 3-4.	6.3	107
216	Novel Oral Anticoagulants. <i>Anesthesiology</i> , 2010, 113, 726-745.	1.3	80

#	ARTICLE	IF	CITATIONS
217	Transfusion Requirements and Outcomes In the Cohort of Patients Undergoing Isolated CABG Treated with Prasugrel or Clopidogrel: TRITON-TIMI 38 Data Analysis.. Blood, 2010, 116, 1108-1108.	0.6	1
218	Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. Thrombosis and Haemostasis, 2009, 102, 765-771.	1.8	44
219	Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. British Journal of Anaesthesia, 2009, 102, 793-799.	1.5	209
220	Is preoperative fibrinogen predictive for postoperative bleeding after coronary artery bypass grafting surgery?. Transfusion, 2009, 49, 2006-2007.	0.8	23
221	A modified recombinant factor VIIa: can we make it work Harder, Better, Faster, Stronger?. Journal of Thrombosis and Haemostasis, 2009, 7, 1514-1516.	1.9	2
222	Blood Coagulation: Hemostasis and Thrombin Regulation. Anesthesia and Analgesia, 2009, 108, 1433-1446.	1.1	281
223	Lack of Clinically Significant Interactions Between the Subcutaneously Administered Direct Thrombin Inhibitor Desirudin and Orally Administered Warfarin Upon the International Normalized Ratio.. Blood, 2009, 114, 3131-3131.	0.6	0
224	Pharmacologic methods to reduce perioperative bleeding. Transfusion, 2008, 48, 31S-38S.	0.8	38
225	Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thrombosis Research, 2008, 122, 117-123.	0.8	88
226	Improved Clot Formation by Combined Administration of Activated Factor VII (NovoSeven®) and Fibrinogen (Haemocomplettan® P). Anesthesia and Analgesia, 2008, 106, 732-738.	1.1	66
227	Perioperative Hemostatic Management of Patients Treated with Vitamin K Antagonists. Anesthesiology, 2008, 109, 918-926.	1.3	143
228	Antithrombin Deficiency Increases Thrombin Activity After Prolonged Cardiopulmonary Bypass. Anesthesia and Analgesia, 2008, 106, 713-718.	1.1	50
229	Low Plasma Fibrinogen Levels with the Clauss Method during Anticoagulation with Bivalirudin. Anesthesiology, 2008, 109, 160-161.	1.3	33
230	Management of surgical hemostasis: systemic agents. Vascular, 2008, 16 Suppl 1, S14-21.	0.4	2
231	Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia. Anesthesia and Analgesia, 2007, 105, 570-582.	1.1	40
232	Clevidipine Effectively and Rapidly Controls Blood Pressure Preoperatively in Cardiac Surgery Patients: The Results of the Randomized, Placebo-Controlled Efficacy Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery-1. Anesthesia and Analgesia, 2007, 105, 918-925.	1.1	103
233	Heparin resistance and the potential impact on maintenance of therapeutic coagulation. European Journal of Anaesthesiology, 2007, 24, 37.	0.7	8
234	Regulation of Thrombin Activity—Pharmacologic and Structural Aspects. Hematology/Oncology Clinics of North America, 2007, 21, 33-50.	0.9	21

#	ARTICLE	IF	CITATIONS
235	Anti-inflammatory Strategies and Hemostatic Agents: Old Drugs, New Ideas. Hematology/Oncology Clinics of North America, 2007, 21, 89-101.	0.9	12
236	Heparin-induced Thrombocytopenia, a Prothrombotic Disease. Hematology/Oncology Clinics of North America, 2007, 21, 65-88.	0.9	43
237	The anticoagulated patient: Strategies for effective blood loss management. Surgery, 2007, 142, S71-S77.	1.0	11
238	The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opinion on Investigational Drugs, 2006, 15, 1077-1090.	1.9	81
239	Massive Transfusion Coagulopathy. Seminars in Hematology, 2006, 43, S59-S63.	1.8	82
240	Should aprotinin continue to be used during cardiac surgery?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 360-361.	3.3	9
241	Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion, 2006, 46, 919-933.	0.8	98
242	Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: yes. Journal of Thrombosis and Haemostasis, 2006, 4, 1875-1878.	1.9	11
243	A Phase III, Double-blind, Placebo-controlled, Multicenter Study on the Efficacy of Recombinant Human Antithrombin in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass. Anesthesiology, 2005, 102, 276-284.	1.3	129
244	Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 107-113.	0.4	121
245	Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan. Thrombosis and Haemostasis, 2005, 94, 808-13.	1.8	9
246	Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation. American Journal of Health-System Pharmacy, 2005, 62, S15-S19.	0.5	12
247	Management of systemic and pulmonary hypertension. Texas Heart Institute Journal, 2005, 32, 467-71.	0.1	15
248	Evaluation and management of bleeding during cardiac surgery. Psychophysiology, 2005, 4, 368-72.	1.1	24
249	Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion, 2004, 44, 1143-1148.	0.8	276
250	Hemostatic agents. Transfusion, 2004, 44, 58S-62S.	0.8	31
251	Safety of aprotinin in heparinized and nonheparinized patients. Journal of Cardiothoracic and Vascular Anesthesia, 2004, 18, S38-S42.	0.6	10
252	Anaphylactic Reactions to Neuromuscular Blocking Drugs: Are We Making the Correct Diagnosis?. Anesthesia and Analgesia, 2004, 98, 881-883.	1.1	15

#	ARTICLE	IF	CITATIONS
253	Aprotinin: A Pharmacologic Overview. <i>Orthopedics</i> , 2004, 27, s653-8.	0.5	29
254	Efficacy and Safety of Aprotinin in Cardiac Surgery. <i>Orthopedics</i> , 2004, 27, s659-62.	0.5	20
255	The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 509-517.	1.4	26
256	Inflammatory response to cardiopulmonary bypass. <i>Annals of Thoracic Surgery</i> , 2003, 75, S715-S720.	0.7	505
257	Novel pharmacologic approaches to reduce bleeding. <i>Canadian Journal of Anaesthesia</i> , 2003, 50, S26-30.	0.7	5
258	Recombinant Human Transgenic Antithrombin in Cardiac Surgery. <i>Anesthesiology</i> , 2002, 96, 1095-1102.	1.3	57
259	The Plasma Supplemented Modified Activated Clotting Time for Monitoring of Heparinization During Cardiopulmonary Bypass: A Pilot Investigation. <i>Anesthesia and Analgesia</i> , 2002, 95, 26-30.	1.1	39
260	Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: Results of a randomized, double-blind trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2002, 124, 35-42.	0.4	554
261	Pharmacologic preservation of the hemostatic system during cardiac surgery. <i>Annals of Thoracic Surgery</i> , 2001, 72, S1814-S1820.	0.7	107
262	Anaphylaxis. What is monitored to make a diagnosis? How is therapy monitored?. <i>Anesthesiology Clinics</i> , 2001, 19, 705-15.	1.4	2
263	Rapid Evaluation of Coagulopathies After Cardiopulmonary Bypass in Children Using Modified Thromboelastography. <i>Anesthesia and Analgesia</i> , 2000, 90, 1324-1330.	1.1	115
264	The In Vitro Effects of Antithrombin III on the Activated Coagulation Time in Patients on Heparin Therapy. <i>Anesthesia and Analgesia</i> , 2000, 90, 1076-1079.	1.1	61
265	Weal and flare responses to intradermal rocuronium and cisatracurium in humans. <i>British Journal of Anaesthesia</i> , 2000, 85, 844-849.	1.5	80
266	Superoxide Production, Risk Factors, and Endothelium-Dependent Relaxations in Human Internal Mammary Arteries. <i>Circulation</i> , 1999, 99, 53-59.	1.6	98
267	Hemostatic agents and their safety. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1999, 13, 6-11; discussion 36-7.	0.6	14
268	Analyses of coronary graft patency after aprotinin use: Results from the international multicenter aprotinin graft patency experience (IMAGE) trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1998, 116, 716-730.	0.4	246
269	Uses of antithrombin III concentrate in congenital and acquired deficiency states. <i>Transfusion</i> , 1998, 38, 481-498.	0.8	61
270	A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting. <i>Circulation</i> , 1995, 92, 2236-2244.	1.6	285

#	ARTICLE	IF	CITATIONS
271	Antithrombin deficiency in special clinical syndromes—Part II: cardiovascular surgery. <i>Seminars in Hematology</i> , 1995, 32, 49-55.	1.8	3
272	Pharmacokinetics of Aprotinin in Preoperative Cardiac Surgical Patients. <i>Anesthesiology</i> , 1994, 80, 1013-1018.	1.3	103
273	The ideal agent for perioperative hypertension and potential cytoprotective effects. <i>Acta Anaesthesiologica Scandinavica</i> , 1993, 37, 20-25.	0.7	31
274	New concepts in the treatment of anaphylactoid reactions in anesthesia. <i>Annales Francaises D'Anesthesie Et De Reanimation</i> , 1993, 12, 223-227.	1.4	15
275	Anaphylactic reactions. <i>Canadian Journal of Anaesthesia</i> , 1992, 39, 95-95.	0.7	0
276	Diagnosis and treatment of anaphylactic/anaphylactoid reactions. <i>Monographs in Allergy</i> , 1992, 30, 130-44.	0.2	9
277	Perioperative experience with amrinone. <i>European Journal of Anaesthesiology Supplement</i> , 1992, 5, 15-9.	0.2	2
278	Effects of protamine on histamine release from human lung. <i>Agents and Actions</i> , 1989, 28, 70-72.	0.7	16
279	Evaluation of patients at risk for protamine reactions. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1989, 98, 200-4.	0.4	17
280	Use of Cardiopulmonary Bypass in Studies of the Circulation. <i>British Journal of Anaesthesia</i> , 1988, 60, 35S-37S.	1.5	16